+++++++++++++++++++++++++++++ + +
+++++++++++++++++++++++++++++ CLINICAL TRIAL REPORT
+++ +++
"Through St.
Luke's Hospital & Health Network's affiliation with
Temple University, we are able to offer many clinical trials. Patients in our area do not need to
travel to New York or Philadelphia
to try a new drug for their disease. We have it all here at home."
— Sanjiv S. Agarwala, M.D., Chief of Medical Oncology
and Hematology at St. Luke's Hospital & Health Network
Providing Patients With Hope
FOR MELANOMA PATIENTS SEEKING TREATMENT AGAINST PROGRESSIVE DISEASE, CLINICAL TRIALS HAVE BECOME A SOURCE OF REFUGE. WITH THE LEADERSHIP OF INTERNATIONALLY RENOWNED PHYSICIAN SANJIV S. AGARWALA, M.D., CHIEF OF MEDICAL ONCOLOGY AND HEMATOLOGY AT ST. LUKE'S HOSPITAL & HEALTH NETWORK, CLINICAL TRIALS HAVE CONTINUED TO OFFER HOPE.
A
CCORDING TO THE American Cancer Society, approxi- mately 70,230 new cases of melanoma will be diagnosed
this year. Until recently, researchers around the world have steadily con- ducted clinical melanoma trials with no significant disease improvement for 30 years. While the disease continues to plague people both young and old, new drugs are notably changing the course of melanoma history.
Behind the Search For more than 15 years, Dr. Agarwala
has dedicated his career to investigating the field of melanoma and immuno- therapy and has led promising clinical trials targeted toward unique therapies. Most recently, he was involved in U.S. Food and Drug Administration (FDA) approval for the drug ipilimumab. "Researchers have always known
immunotherapies could be effective in the battle against melanoma," says
16 | Eastern Pennsylvania/NW New Jersey MD NEWS MDNEWS.COM
Dr. Agarwala. "While clinical studies have ushered in progress with drugs such as interferon, interleukin-2 and vemurafenib, we have never seen such a positive trial as we have with the drug ipilimumab."
New Drugs Combating Cancer For years, melanoma patients have
waited on a new and more promising drug to receive the FDA's stamp of approval. Now, patients have been presented with ipilimumab, as well as vemurafenib,